Marinus Pharmaceuticals’ (MRNS) stock rallied following its announcement of top-line data from Phase 2 open-label study in patients with the severe epilepsy disorder known as CDKL5. The disease is a rare severe genetic derived epilepsy that results in seizures, pervasive neuro-developmental delay and disabling behavioral issues. The disease has no approved treatments.
The good news that boosted the stock price early today has come out of the results demonstrating that oral ganaxolone has durable seizure-frequency reduction in the majority of patients. Some of the patients achieved an increase in the number of . . .